OrganiGram vs Marathon

OrganiGram Holdings Inc. and Marathon Petroleum Corporation are two companies from distinct industries, but both have captured the attention of investors looking to diversify their portfolios. OrganiGram, a Canadian cannabis producer, has seen impressive growth in the emerging marijuana market. On the other hand, Marathon, a leading petroleum refining company, has had consistent performance in the energy sector. Both companies have unique market positions and potential for future growth, making them intriguing options for investors seeking high potential stocks.

OrganiGram or Marathon?

When comparing OrganiGram and Marathon, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between OrganiGram and Marathon.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. OrganiGram has a dividend yield of -%, while Marathon has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. OrganiGram reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Marathon reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with OrganiGram P/E ratio at -3.39 and Marathon's P/E ratio at 0.00. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. OrganiGram P/B ratio is 0.84 while Marathon's P/B ratio is 0.00.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, OrganiGram has seen a 5-year revenue growth of 3.45%, while Marathon's is 0.00%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with OrganiGram's ROE at -26.61% and Marathon's ROE at 0.00%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $1.70 for OrganiGram and $0.00 for Marathon. Over the past year, OrganiGram's prices ranged from $0.97 to $2.91, with a yearly change of 200.00%. Marathon's prices fluctuated between $0.00 and $0.00, with a yearly change of 9900.00%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.